Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Hold” from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received an average recommendation of “Hold” from the ten ratings firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.1429.

Several research analysts have weighed in on the company. Mizuho boosted their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, September 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Saturday, September 27th.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter worth $770,000. California State Teachers Retirement System increased its holdings in shares of Neumora Therapeutics by 793.5% during the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company’s stock worth $577,000 after buying an additional 48,362 shares during the last quarter. Lunate Capital Ltd acquired a new stake in shares of Neumora Therapeutics during the 1st quarter worth $2,124,000. Cerity Partners LLC increased its holdings in Neumora Therapeutics by 24.0% in the 1st quarter. Cerity Partners LLC now owns 302,505 shares of the company’s stock valued at $303,000 after purchasing an additional 58,597 shares in the last quarter. Finally, CWM LLC increased its holdings in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company’s stock valued at $25,000 after purchasing an additional 24,864 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Up 2.8%

Shares of NMRA opened at $1.83 on Friday. The stock has a fifty day moving average of $1.70 and a two-hundred day moving average of $1.19. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.54 and a current ratio of 10.54. The company has a market capitalization of $296.37 million, a PE ratio of -1.17 and a beta of 2.92. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.05. As a group, analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.